518 related articles for article (PubMed ID: 30625282)
1. Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.
Chun J; Kihara Y; Jonnalagadda D; Blaho VA
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():149-170. PubMed ID: 30625282
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
3. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Chun J; Brinkmann V
Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
[TBL] [Abstract][Full Text] [Related]
4. Lessons from S1P receptor targeting in multiple sclerosis.
Colombo E; Farina C
Pharmacol Ther; 2022 Feb; 230():107971. PubMed ID: 34450231
[TBL] [Abstract][Full Text] [Related]
5. Roles for lysophospholipid S1P receptors in multiple sclerosis.
Noguchi K; Chun J
Crit Rev Biochem Mol Biol; 2011 Feb; 46(1):2-10. PubMed ID: 20979571
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.
Bordet R; Camu W; De Seze J; Laplaud DA; Ouallet JC; Thouvenot E
Rev Neurol (Paris); 2020; 176(1-2):100-112. PubMed ID: 31757428
[TBL] [Abstract][Full Text] [Related]
9. Morpholino Analogues of Fingolimod as Novel and Selective S1P
Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
[TBL] [Abstract][Full Text] [Related]
10. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling.
Chew WS; Wang W; Herr DR
Pharmacol Res; 2016 Nov; 113(Pt A):521-532. PubMed ID: 27663260
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine-1-phosphate receptor modulators in stroke treatment.
Zhang W; Li Y; Li F; Ling L
J Neurochem; 2022 Sep; 162(5):390-403. PubMed ID: 35943290
[TBL] [Abstract][Full Text] [Related]
12. The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.
Mao-Draayer Y; Sarazin J; Fox D; Schiopu E
Clin Immunol; 2017 Feb; 175():10-15. PubMed ID: 27890706
[TBL] [Abstract][Full Text] [Related]
13. The S1P mimetic fingolimod phosphate regulates mitochondrial oxidative stress in neuronal cells.
Martín-Montañez E; Pavia J; Valverde N; Boraldi F; Lara E; Oliver B; Hurtado-Guerrero I; Fernandez O; Garcia-Fernandez M
Free Radic Biol Med; 2019 Jun; 137():116-130. PubMed ID: 31035004
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
15. Lysophospholipids and their receptors in the central nervous system.
Choi JW; Chun J
Biochim Biophys Acta; 2013 Jan; 1831(1):20-32. PubMed ID: 22884303
[TBL] [Abstract][Full Text] [Related]
16. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
Kihara Y; Chun J
Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and Optimization of
Gusman DH; Shoemake C
Yale J Biol Med; 2017 Mar; 90(1):15-23. PubMed ID: 28356890
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.
Tsai HC; Han MH
Drugs; 2016 Jul; 76(11):1067-79. PubMed ID: 27318702
[TBL] [Abstract][Full Text] [Related]
19. Second generation S1P pathway modulators: research strategies and clinical developments.
Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
[TBL] [Abstract][Full Text] [Related]
20. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
